食管或食管胃交界腺癌风险预测工具的验证
该研究基于Kaiser Permanente北加州社区队列206,974人,随访至2016年,比较验证4种工具对食管腺癌(EAC)和食管胃交界腺癌(EGJAC)的预测能力。结果发现GERD症状仅预测EAC(HR 2.66),而Kunzmann等工具预测EAC更准确,Kunzmann第四分位风险为第一分位的16.7倍;各工具对EGJAC预测效应较弱。
要点
- GERD症状可预测EAC(HR 2.66),但不预测EGJAC。
- Kunzmann工具预测EAC校准最佳,第四分位HR 16.7。
- 各工具对EGJAC预测效应较弱,但仍优于单用GERD。
核心结论
- 研究独立验证了4种工具可预测EAC和EGJAC,Kunzmann工具校准最佳,均优于单用GERD进行风险分层。
研究设计与样本
- 回顾性纵向分析Kaiser Permanente北加州多相健康检查队列,纳入1964–1973年入组的206,974名患者,随访至2016年。
- 基线问卷和人体测量数据用于分类各工具的预测变量,并与癌症登记结局链接。
- 分析采用逻辑回归、Cox比例风险回归和Kaplan-Meier生存曲线。
主要发现
- 随访至入组后平均32年,识别168例新发EAC和151例新发EGJAC(对照平均随访26年)。
- GERD症状预测新发EAC(HR 2.66;95%CI 1.01–7.00),但不预测EGJAC。
- Nord-Trøndelag健康研究工具、Kunzmann工具和Michigan Barrett食管预测工具预测EAC比GERD更准确。
- Kunzmann工具第四分位个体EAC风险为第一分位的16.7倍(HR=16.7;95%CI 4.72–58.8)。
- 各工具也预测新发EGJAC,但效应幅度较小。
关键数值与推荐
- GERD症状预测EAC的HR为2.66(95%CI 1.01–7.00)。
- Kunzmann工具第四分位 vs 第一分位预测EAC的HR为16.7(95%CI 4.72–58.8)。
临床怎么用
- 临床可考虑使用经验证的工具(如Kunzmann)替代单用GERD症状进行EAC和EGJAC风险分层。
- 工具在社区人群中验证,但如何最佳融入临床实践尚待未来研究确定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Guidelines suggest screening of individuals who are at increased risk of esophageal adenocarcinoma (EAC). Tools for identifying patients at risk of Barrett's esophagus have been validated. Here, we aimed to compare and validate the tools for the primary outcomes of interest: EAC and esophagogastric junction adenocarcinoma (EGJAC). METHODS: Retrospective longitudinal analysis of the Kaiser Permanente Northern California Multiphasic Health Checkup Cohort, a community-based cohort including 206,974 patients enrolled between 1964 and 1973 followed through 2016. Baseline questionnaires and anthropometrics classified predictor variables for each tool and were linked to cancer registry outcomes. Analyses used logistic regression, Cox proportional hazards regression, and Kaplan-Meier survival curves. RESULTS: We identified 168 incident EAC cases and 151 EGJAC cases at a mean of 32 years after enrollment (mean follow-up among controls 26 years). Gastroesophageal reflux disease (GERD) symptoms predicted incident EAC (hazard ratio 2.66; 95% confidence interval 1.01, 7.00), but not EGJAC. The Nord-Trøndelag Health Study tool, Kunzmann tool, and Michigan Barrett's Esophagus pREdiction Tool were more accurate than GERD for predicting EAC, with individuals in the fourth quartile of Kunzmann having 17-fold the risk of those in the 1st quartile (hazard ratio = 16.7, 95% confidence interval = 4.72, 58.8). Each tool also predicted incident EGJAC with smaller magnitudes of effect. DISCUSSION: The study independently validated 4 tools for predicting incident EAC and EGJAC in a large community-based population. The Kunzmann tool appears best calibrated; all appear preferable to using GERD alone for risk stratification. Future studies should determine how best to implement such tools into clinical practice.
引用
- Rubenstein JH, Raghunathan T, Doan C, et al. Validation of Tools for Predicting Incident Adenocarcinoma of the Esophagus or Esophagogastric Junction. Am J Gastroenterol. 2021. PMID: 33852454. doi:10.14309/ajg.0000000000001255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。